BAY 55-9837 (trifluoroacetate salt)

Formulation: A solid

Formal Name: L-histidyl-L-seryl-L-α-aspartyl-L-alanyl-L-valyl-L-phenylalanyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-tyrosyl-L-threonyl-L-arginyl-L-leucyl-L-arginyl-L-lysyl-L-glutaminyl-L-valyl-L-alanyl-L-alanyl-L-lysyl-L-lysyl-L-tyrosyl-L-leucyl-L-glutaminyl-L-seryl-L-isoleucyl-L-lysyl-L-asparaginyl-L-lysyl-L-arginyl-L-tyrosinamide, trifluoroacetate salt

Purity: ≥98%

Formula Markup: C167H270N52O46 • XCF3COOH

Formula Weight: 3742,3

Shelf life (days): 1460

Notes: BAY 55-9837 is a peptide vasoactive intestinal polypeptide receptor 2 (VPAC2) agonist.{66469} It binds to VPAC2 (Kd = 65 nM) and selectively induces cAMP production in CHO cells expressing human VPAC2 over VPAC1 or the PACAP type I (PAC1) receptor (EC50s = 0.4, 100, and >1,000 nM, respectively). BAY 55-9837 (100 nM) increases glucose-dependent insulin secretion in isolated rat and human pancreatic islets. In vivo, BAY 55-9837 enhances glucose-induced insulin secretion in fasted rats (ED50 = ~3 pmol/kg).

• SKU: CAY36752-25
• Manufacturer: Cayman Chemical
• Manufacturer SKU: 36752-25
• Package Unit: 25 mg
• Quantity Unit: STK